270 related articles for article (PubMed ID: 35251585)
1. Idiopathic multicentric Castleman disease treated with siltuximab for 15 years: a case report.
Lang E; Sande B; Brodkin S; van Rhee F
Ther Adv Hematol; 2022; 13():20406207221082552. PubMed ID: 35251585
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Tolerance and Efficacy of Siltuximab (Anti-IL-6) in a Young Adult with Idiopathic Multicentric Castleman Disease During COVID-19.
Bedier H; Isnard S; Maedler-Kron C; Routy JP
Eur J Case Rep Intern Med; 2023; 10(12):004098. PubMed ID: 38077710
[TBL] [Abstract][Full Text] [Related]
3. Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy.
Cohen PR; Nikanjam M; Kato S; Goodman AM; Kurzrock R
Cureus; 2020 Jul; 12(7):e8967. PubMed ID: 32766009
[TBL] [Abstract][Full Text] [Related]
4. Siltuximab: a targeted therapy for idiopathic multicentric Castleman disease.
Fajgenbaum DC; Kurzrock R
Immunotherapy; 2016; 8(1):17-26. PubMed ID: 26634298
[TBL] [Abstract][Full Text] [Related]
5. Dichotomic response to interleukin-6 blockade in idiopathic multicentric Castleman disease: two case reports.
Ferrero S; Ragaini S
J Med Case Rep; 2021 Mar; 15(1):105. PubMed ID: 33676575
[TBL] [Abstract][Full Text] [Related]
6. Siltuximab is associated with improved progression-free survival in idiopathic multicentric Castleman disease.
van Rhee F; Rosenthal A; Kanhai K; Martin R; Nishimura K; Hoering A; Fajgenbaum DC
Blood Adv; 2022 Aug; 6(16):4773-4781. PubMed ID: 35793409
[TBL] [Abstract][Full Text] [Related]
7. Therapy of Castleman's disease with siltuximab - case report and review of literature.
Adam Z; Zeman D; Chodacki A; Pour L; Horváth T; Benda P; Adamová Z; Krejčí M; Tomíška M; Boichuk I; Král Z
Klin Onkol; 2023; 37(4):320-329. PubMed ID: 38195387
[TBL] [Abstract][Full Text] [Related]
8. A challenging diagnosis of idiopathic multicentric Castleman disease with complex systemic presentation: A case report.
Strach M; Kuszmiersz P; Chmura Ł; Korkosz M
Clin Case Rep; 2023 Oct; 11(10):e7981. PubMed ID: 37854256
[TBL] [Abstract][Full Text] [Related]
9. POEMS Syndrome: Presented as Idiopathic Multicentric Castleman Disease of Plasma Cell Variant for Eight Years and Dramatic Treatment with Siltuximab Followed by Autologous Peripheral Blood Stem Cell Transplantation.
Lee YM; Choi YS; Kim JM
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35454046
[TBL] [Abstract][Full Text] [Related]
10. Siltuximab: A Review in Idiopathic (Human Herpesvirus-8-Negative) Multicentric Castleman Disease.
Lyseng-Williamson KA
BioDrugs; 2015 Dec; 29(6):399-406. PubMed ID: 26394632
[TBL] [Abstract][Full Text] [Related]
11. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
Morra DE; Pierson SK; Shilling D; Nemat S; Appiani C; Guilfoyle M; Tendler C; van Rhee F; Fajgenbaum DC
Br J Haematol; 2019 Jan; 184(2):232-241. PubMed ID: 30203839
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
van Rhee F; Casper C; Voorhees PM; Fayad LE; Gibson D; Kanhai K; Kurzrock R
Lancet Haematol; 2020 Mar; 7(3):e209-e217. PubMed ID: 32027862
[TBL] [Abstract][Full Text] [Related]
13. Utility of renal biopsy in differentiating idiopathic multicentric Castleman disease from IgG4-related disease.
Kawanishi M; Kamei F; Sonoda H; Oba M; Fukunaga S; Egawa M; Koyama T; Sato Y; Tanabe K; Ito T
CEN Case Rep; 2023 May; 12(2):242-248. PubMed ID: 36414812
[TBL] [Abstract][Full Text] [Related]
14. Are Patients with HHV-8 Associated Castleman Disease Successfully Treated with Rituximab at Risk of Subsequently Developing HHV-8 Negative (Idiopathic) Castleman Disease?
Ha G; Kwong K; Tanaka B; Nishimura Y; Chong C
Eur J Case Rep Intern Med; 2023; 10(7):003904. PubMed ID: 37455698
[TBL] [Abstract][Full Text] [Related]
15. TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.
Williams C; Phillips A; Aggarwal V; Slonim LB; Fajgenbaum DC; Karmali R
Case Rep Oncol; 2021; 14(3):1359-1365. PubMed ID: 34720942
[TBL] [Abstract][Full Text] [Related]
16. Idiopathic multicentric Castleman disease with pulmonary and cutaneous lesions treated with tocilizumab: A case report.
Han PY; Chi HH; Su YT
World J Clin Cases; 2020 Oct; 8(20):4922-4929. PubMed ID: 33195662
[TBL] [Abstract][Full Text] [Related]
17. Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival.
Gao YH; Liu YT; Zhang MY; Li SY; Fajgenbaum DC; Zhang L; Li J
Br J Haematol; 2024 May; 204(5):1830-1837. PubMed ID: 38356434
[TBL] [Abstract][Full Text] [Related]
18. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria.
Zhang L; Dong YJ; Peng HL; Li H; Zhang MZ; Wang HH; Liu QH; Su LP; Zhong LY; Wu WJ; Huang L; Yan XJ; Fan L; Tang WJ; Li ZL; Bi LT; Li Y; Gao GX; Gao L; Liu TB; Wei YQ; Liu Y; Yu L; Zhou H; Sun CY; Qian WB; Zou DH; Zhang HL; Ding KY; Wang XB; Bai O; Huang WR; Chen B; Yang L; Song J; Gao D; Chen T; Luo J; Wang SY; Ma LM; Fajgenbaum DC; Li J;
Lancet Reg Health West Pac; 2023 May; 34():100720. PubMed ID: 37283978
[TBL] [Abstract][Full Text] [Related]
19. The clinical, laboratory, and radiologic improvement due to siltuximab treatment in idiopathic multicentric Castleman's disease.
Min GJ; Jeon YW; Park SS; Park S; Shin SH; Yahng SA; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Kim DW; Lee JW; Cho SG
Korean J Intern Med; 2021 Mar; 36(2):424-432. PubMed ID: 32088937
[TBL] [Abstract][Full Text] [Related]
20. Schnitzler syndrome co-occurring with idiopathic multicentric Castleman disease that responds to anti-IL-1 therapy: A case report and clue to pathophysiology.
Soudet S; Fajgenbaum D; Delattre C; Forestier A; Hachulla E; Hatron PY; Launay D; Terriou L
Curr Res Transl Med; 2018 Sep; 66(3):83-86. PubMed ID: 30108026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
